Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
EPS Growth %: +30.8%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +30.8%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.16), $0.06 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $30.09 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $125-135 million, versus the consensus of $128 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
